Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — frontier options in Texas
30 open options
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
ITI-1284 · Placebo — 70 sites
- TRIALPHASE3RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Xanomeline/Trospium Chloride Capsule · Xanomeline Enteric Capsule · Placebo — 159 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Placebo (Study Part 1a) · ACI-24.060 at Dose A in Study Part 1a · ACI-24.060 at Dose B in Study Part 1a — 26 sites
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
KarXT · Placebo — 129 sites
- TRIALPHASE4RECRUITING
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
Gabapentin Enacarbil · Placebo Oral Tablet — 1 site
- TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 212 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
ABBV-1758 · Placebo for ABBV-1758 · ABBV-1758 — 12 sites
- TRIALPHASE3RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Xanomeline/Trospium Chloride Capsule · Xanomeline Enteric Capsule · Placebo — 145 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug (SC) · Matching Placebo (Remternetug) — 37 sites
- TRIALNARECRUITING
IHT for Mild Cognitive Impairment
IHT Treatment · Sham-IHT Control — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug · Matching Placebo (Remternetug) — 37 sites
- TRIALPHASE2 / PHASE3RECRUITING
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACP-204 · Placebo — 148 sites
- TRIALNARECRUITING
Enhancing Attention in Elderly Using a Brain-Computer-Interface
transcranial electrical stimulation · Mindfulness Meditation — 2 sites
- TRIALPHASE3RECRUITING
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Donanemab · Placebo — 59 sites
- TRIALNARECRUITING
Remotely-supervised Neuromodulation in PPA
Lexical Retrieval Cascade Treatment · Remotely Supervised Transcranial Direct Current Stimulation- Active · Remotely Supervised Transcranial Direct Current Stimulation - Sham — 2 sites
- TRIALPHASE3RECRUITING
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Masupirdine 50 mg · Masupirdine 100 mg · Placebo — 44 sites
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
KarXT · Placebo — 154 sites
- TRIALNARECRUITING
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
LOCK Sleep Program · No intervention (control period/baseline data collection) — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
Stem Cell Therapy for Early Alzheimer's Disease
adMSC — 1 site
- TRIALPHASE2RECRUITING
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
LHP588 · LHP588 · Placebo Drug — 40 sites
- TRIALPHASE2RECRUITING
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
BMS-986368 · Placebo — 75 sites
- TRIALEARLY_PHASE1RECRUITING
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
Glycine · N-acetylcysteine · Alanine — 1 site
- TRIALNARECRUITING
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
Blood Brain Barrier (BBB) Disruption — 10 sites
- TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
- TRIALPHASE3RECRUITING
[18F]PI-2620 Phase 3 Histopathological Study
[18F]PI-2620 — 25 sites
- TRIALNAENROLLING_BY_INVITATION
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
Sensory Stimulation System (GS120) - Active — 53 sites
- TRIALNARECRUITING
Cognitive Screening Made Easy for PCPs - Administrative Supplement
RACS app — 3 sites
- TRIALPHASE3ENROLLING_BY_INVITATION
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
ACP-204 — 76 sites
- TRIALNAENROLLING_BY_INVITATION
Speech-Language Treatment With Remotely Supervised Transcranial Direct Current Stimulation in Primary Progressive Aphasia
Remotely supervised Transcranial Direct Current Stimulation (RS-tDCS) · Remotely supervised sham tDCS (RS-sham-tDCS) · Lexical Retrieval Training (LRT) — 2 sites
- TRIALPHASE1 / PHASE2RECRUITING
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
IL-2 (Aldesleukin) · Semaglutide Plus IL-2 · Placebo — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.